
Abstract Introduction Tobacco use has consistently been linked to suicide risk, and some data suggest that tobacco cessation may reduce risk. However, higher risk individuals are typically excluded from clinical trials. Dialectical Behavior Therapy is a psychotherapy approach originally designed to reduce suicide risk that may also be beneficial in treating addiction by enhancing emotion regulation and distress tolerance skills. Methods The present study was a randomized pilot trial comparing a standard tobacco cessation intervention to a DBT-based integrated intervention for tobacco cessation and suicide prevention. Veterans (n = 68) who were daily users of cigarettes and/or e-cigarettes were randomized to DBT for cessation (DBT-C) or to treatment as usual (TAU). Participants in both conditions attended 12 weekly group psychotherapy sessions and were followed for a total of 24 weeks to evaluate changes in tobacco use, suicidality, emotion regulation and overall satisfaction with the intervention. Results DBT-C and TAU participants did not differ in terms of abstinence at end-of-treatment or 24-week follow-up. There was a trend toward greater improvement in emotion regulation in DBT-C versus TAU. Participants generally were satisfied with the intervention. Conclusions This pilot trial provides preliminary evidence that individuals who use tobacco and are at elevated suicide risk can be effectively engaged in tobacco cessation interventions, and that such interventions may benefit emotional functioning as well as reducing tobacco use. DBT-C appears to be a potentially effective approach but additional, larger-scale research is needed to enable a more thorough assessment.
Abstract Introduction Tobacco cessation is a public health priority. However, long-term outcomes remain limited, partly due to insufficient adaptation of interventions to chronic conditions, such as diabetes mellitus (DM), a leading cause of chronic disability worldwide. Evidence regarding the clinical impact of smoking cessation treatments in people with DM remains inconsistent. The objective of this study was to examine the effectiveness of psychological smoking cessation interventions for individuals with type 1 and type 2 DM. Methods A search for scientific studies was conducted in four databases (PubMed, Web of Science, SCOPUS, and PsycINFO), resulting in the selection of 12 studies following PRISMA guidelines (PROSPERO, ID: CRD42024531545). Results Overall, 83.3% of the interventions incorporated diabetes-adapted components. Programs frequently achieved short-term reductions in cigarette consumption, although complete long-term abstinence was less frequent. Only a minority of studies demonstrated statistically significant higher abstinence rates in the intervention groups than in the control groups, ranging from 31.3% to 70.6% at 6 months and 20.0% to 38.8% at 12 months. The most favorable outcomes occurred in group-based, multicomponent programs for type 2 DM combining diabetes-specific psychoeducation, motivational strategies, and optional pharmacotherapy. Conclusions Due to a moderate-to-high risk of bias across studies, evidence regarding the effectiveness of psychological smoking cessation interventions for individuals with DM remains limited. Further research is needed to identify factors that influence smoking cessation outcomes in patients with DM. The integration of evidence-based programs and interventions tailored to diabetes-related needs, associated comorbidities, and gender-specific factors are essential to address these challenges.
Abstract Tobacco use is a leading cause of morbidity and mortality worldwide. Despite efficacious interventions, smoking cessation remains difficult for many individuals. While demographic and behavioural predictors of smoking cessation outcomes are well-documented, neurobiological predictors of success have been inconsistent across studies. The current systematic review aimed to identify neuroimaging biomarkers consistently associated with smoking cessation success. A systematic search identified 32 studies that examined neural predictors of outcomes across structural and functional magnetic resonance imaging modalities and intervention types. The most frequently implicated brain regions included the medial prefrontal cortex (PFC), striatum, and anterior insula. Specifically, greater medial PFC response to health promotion tasks; greater reactivity to smoking-related cues in the dorsolateral PFC and dorsal striatum; stronger resting state functional connectivity between the insula and dorsal anterior cingulate cortex, precuneus, and medial frontal gyrus; and greater global gray matter volume were commonly reported as predictors of better treatment response. The current systematic review identifies the most robust MRI biomarkers of smoking cessation, but in a relatively small overall literature with extensive heterogeneity among studies.
ABSTRACT Introduction In response to the growing popularity of e-cigarettes globally, particularly among younger non-smokers, many countries have introduced restrictions around the flavours of e-cigarette products. In Australia, current legislation restricts e-cigarettes to only tobacco, menthol and mint but does not specify the flavouring chemicals that may impart these flavours. Methods A convenience sample of e-liquids (N = 81), pods (N = 16) and disposable e-cigarettes (N = 43) that were “tobacco”, “mint” or “menthol” flavoured were selected for analysis. Their chemical composition was determined using gas chromatography-mass spectrometry (GC-MS). Results Most tobacco flavoured samples contained ethyl maltol (86.7%), a caramellic flavoured chemical. While no flavouring chemicals known to impart a tobacco flavour were identified, the synthetic coolant WS-23 was absent or detected in lower concentrations compared to sweet e-cigarette products analysed previously. A coolant chemical (menthol, WS-23 or WS-3) was detected in all mint/menthol samples, although many also contained fruity (26.2%), vanilla (19.7%) and caramellic (19.7%) flavouring chemicals, often with no indication in the flavour name. Conclusions The composition of the tobacco flavoured samples was similar to prohibited sweeter e-cigarette products, with no common flavour chemicals identified which could be attributed to a tobacco flavour. The lack of coolants in tobacco flavoured e-cigarettes may increase their throat harshness, potentially aligning them more with the sensory experience of traditional cigarettes. While all mint/menthol samples contained coolants, fruity and sweet flavouring chemicals, characteristic of the products prohibited under the current legislation, were still detected in some samples.